Princess Alexandra Hospital 3 articles published in JoVE Cancer Research Culture of Bladder Cancer Organoids as Precision Medicine Tools Patrick B. Thomas1,2,3,4, Mahasha P. J. Perera1,2,3,4,5, Saeid Alinezhad1,4, Andre Joshi1,4,5, Paria Saadat1,2, Clarissa Nicholls1,2, Caitlin P. Devonport1,2,4, Alivia R. Calabrese1,2,3,4, Abby R. Templeton1,2,3, Jack R. Wood1,2, Nathan J. Mackenzie1,2, Penny L. Jeffery1,2,3,4, Ian Vela*1,2,3,4,5, Elizabeth D. Williams*1,2,3,4 1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT) at Translational Research Institute, 2Queensland Bladder Cancer Initiative (QBCI), 3Centre for Personalised Analysis of Cancers (CPAC), 4Australian Prostate Cancer Research Centre - Queensland, 5Department of Urology, Princess Alexandra Hospital Patient-derived organoids (PDOs) are a powerful tool in translational cancer research, reflecting both the genetic and phenotypic heterogeneity of the disease and response to personalized anti-cancer therapies. Here, a consolidated protocol to generate human primary bladder cancer PDOs in preparation for the evaluation of phenotypic analyses and drug responses is detailed. Medicine Absorbent Microbiopsy Sampling and RNA Extraction for Minimally Invasive, Simultaneous Blood and Skin Analysis Benson U.W. Lei1,2, Miko Yamada1, Van L.T. Hoang3, Paul J. Belt4, Mark H. Moore5, Lynlee L. Lin2, Ross Flewell-Smith1, Nhung Dang1,2, Shoko Tomihara2, Tarl W. Prow1,2 1Future Industries Institute, University of South Australia, 2Faculty of Medicine, University of Queensland, 3Faculty of Health, Queensland University of Technology, 4Department of Plastic and Reconstructive Surgery, Princess Alexandra Hospital, 5Australian Craniofacial Unit, Women's and Children's Hospital In this article, we demonstrate how the absorbent microbiopsy technique is performed and how the sample can be used for RNA extraction for simple and simultaneous sampling of skin and blood in a minimally invasive manner. Medicine Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance Chayanika Biswas*1, Sharon C-A. Chen*1,2,3, Catriona Halliday1,2, Elena Martinez1, Rebecca J. Rockett1, Qinning Wang1, Verlaine J. Timms1, Rajat Dhakal1, Rosemarie Sadsad1, Karina J. Kennedy4, Geoffrey Playford4,5, Deborah J. Marriott6, Monica A. Slavin7, Tania C. Sorrell1,3, Vitali Sintchenko1,2,3 1Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, 2Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, 3Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, 4Department of Microbiology and Infectious Diseases, Canberra Hospital and Health Services, Australian National University Medical School, 5Infection Management Services, Australian National University Medical School, 6 This study implemented whole genome sequencing for analysis of mutations in genes conferring antifungal drug resistance in Candida glabrata. C. glabrata isolates resistant to echinocandins, azoles and 5-flucytosine, were sequenced to illustrate the methodology. Susceptibility profiles of the isolates correlated with presence or absence of specific mutation patterns in genes.
